Exosomes bearing functional MHC-peptide complexes have been shown to be presented at the surface of recipient DCs as intact "antigen-presenting microdomains", without the need for internalisation and reprocessing by the DC.

These T cells were obtained from isolation during elutriation and were used for subsequent adoptive transfer.

Expression vectors for GFP-RIG-I used to analyse the interaction between RIG-I, a viral sensing protein, and NS1, an inhibitor of interferon production that is encoded by influenza A virus have been made available.

Total RNA was extracted from yeast cells after buffering, incubation and centrifugation by phenol extraction.

Fabs that bind strongly to L-SIGN, but to a lesser degree or not at all to dendritic cell-specific ICAM-grabbing nonintegrin (DC-SIGN) were isolated and characterized. We believe that the isolated Abs may be useful for selective delivery of Ags to DC-SIGN- or L-SIGN-bearing APCs for the modulation of immune responses and for blocking viral infections.

The FC-block was used for incubation of cells (1:50 in PBS + 2 % FCS) for FACS staining of activation markers.

These mice were generated with the intention to elucidate in vivo DC developmental regions in steady state and inflammation in situ.

We found a novel M-CSF dependent DC developmental pathway that is independent of Flt3L. These DC have unique characteristics and precursor origin. The cells can be found in vivo in Flt3L gene deleted (-/-) mice injected with recombinant M-CSF.

The mice were generated with the intention to elucidate in vivo DC developmental regions in steady state and inflammation in situ.

We found that the cooperation between IFNalpha,beta and Flt3L (FL) plays an important role in the defense against Herpes simplex virus type 1 (HSV-1) in neonates. Treatment of neonatal mice with recombinant IFNalpha has a short-term, FL-independent and a long-term, FL-dependent protective effect against HSV-1. In mice lacking FL, neonatal resistance against HSV-1 is very low and DC numbers in the spleen are reduced. The treatment of these mice with rIFNalpha at day 6 resulted in an increased resistance against infection with HSV-1 at day 7. In C57BL/6 mice, tr...

1,25(OH)2D3 was added to the freshly isolated monocytes; this prevented the generation of IFN-DCs and directed already differentiated IFN-DCs toward a more immature stage.

All lymphocytes (6,4 x 10e9) were frozen in 90% A-plasma and 10% GMP-grade DMSO.

The mature peptide pulsed DC were frozen at 5 x 10e6 cells per vial in freezing medium for subsequent stimulation of autologous T cells.

The majority of monocytes (1 x 10e9) were frozen in 90% A-plasma and 10% GMP-grade DMSO.

Tests were performed on frozen peripheral blood leukocytes (PBL) obtained from leukapheresis or buffy-coat collections performed before and after the 6 vaccinations in Cycle 1 and after the 3 vaccinations of Cycle 2. The fresh PBL samples were collected from UTCM (Hôpital Erasme, ULB) and were transferred to Ludwig Institute where the freezing of the samples and analyses were performed.

Down-regulation of CD83 expression on human DC through RNA interference (RNAi) results in a less potent induction of allogeneic T cell proliferation, reduced IFN-gamma secretion by established T cells and decreased capacity in the priming of functional tumor antigen-specific CD8+ T lymphocytes.

DCs with blocked beta-glucan, mannan and chitin receptors were exposed to these fungi.

Untouched naive CD4+ T cells are co-coltured with fungi -pulsed DCs with the aim to prime naive T cells.

These dendritic cells were generated with GM-CSF and IL-4. They were used in a clinical trial in melanoma patients who were randomized to receive immunizations either with these G4 DC or with I3 DC (DC generated with interferon-beta and interleukin-3).

This patient has received 6 vaccines with peptide only in a randomized trial to receive immunizations either with I3 DC (DC generated with interferon-beta and interleukin-3) or with G4 DC (DC generated with GM-CSF and IL-4). The patient received a sequence of six immunizations every two weeks, consisting of autologous dendritic cells loaded with the 8 HLA-A2 restricted peptides and MAGE.3-DP4 in Cycle 1. In Cycle 2, the patient received a sequence of three immunizations every six weeks, consisting of autologous dendritic cells loaded with the 8 HLA-A2 restric...